Table 1.

Characterization of the single-nucleotide polymorphisms (SNPs) described in recent pharmacogenetic studies of the therapeutic response to bronchodilators or inhaled corticosteroids in asthma.

SNP	Score PharmGKB	Gene	Outcome	Reference
rs11681246	-	LTBP1	Negatively associated with asthma exacerbations regardless of ICS use	[20]
rs76390075	-	LTBP1		[20]
rs73650726	-	LOC105376110	Negatively associated with BDR	[21]
rs7903366	-	PRKG1	Positively associated with the BDR	[21]
rs7081864	-	PRKG1	Positively associated with the BDR	[21]
rs7070958	-	PRKG1	Negatively associated with the BDR	[21]
rs1042713	2A	ADRB2	Better response to treatment with A allele	[24,30]
			Worst response to treatment with A allele	[29]
			No association with therapeutic response	[25,32,34]
rs1042714	-	ADRB2	Better response to treatment	[23,29]
			No association with therapeutic response	[24,27,30,34]
rs1042713/rs1042714	-	ADRB2	Better response to treatment	[35]
rs180888	-	ADRB2	Uncontrolled asthma during LABA treatment	[28]
rs37972	-	GLCCI1	Attenuation of the response to ICS treatment	[41]
rs37973	3	GLCCI1	Worst response to treatment with G Allele	[38,40,41]
			Better response to treatment with G allele	[42]
rs2228570	-	VDR	Risk of resistance to inhaled glucocorticoids	[46]
			Higher exacerbation severity scores and poorer β2-agonist treatment response	[47]